\n\n(1)<\/sup><\/p><\/td>\nPlease refer to the \u201cExplanation of Non-GAAP Financial Measures\u201d section.<\/p><\/td><\/tr>\n | \n| \n | \u00a0<\/td>\n<\/tr>\n<\/table> \nInvestor Conference Call and Webcast<\/b><\/p> \nAs previously disclosed, Veradigm management plans to host an investor conference call and webcast to discuss the Company\u2019s update on Wednesday, May 27, 2026, at 8:00 a.m. Eastern Time.<\/p> \nTo listen to the conference call, participants may log onto the Veradigm investor relations website<\/a>. Participants also may access the conference call by dialing 877-405-1224 or 201-389-0848 and requesting Access ID # 13760831.<\/p>\nA replay of the call will be available for a period of one year on the Veradigm investor relations website<\/a>.<\/p>\nAbout Veradigm\u00ae<\/b><\/p> \nVeradigm has a proven history of delivering clinical and revenue cycle solutions that help independent practices improve outcomes and financial performance. Our AI-forward data and technology also help over 20,000 provider practices connect with health plans and biopharma to eliminate inefficiencies, close care gaps, and create a more affordable health system.<\/p> \n\u00a9 2026 Veradigm LLC and\/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and\/or its affiliates. All other product or Company names are the property of their respective holders, all rights reserved.<\/p> \nDisclaimer and Forward-Looking Statement Information<\/b><\/p> \nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company\u2019s preliminary estimated unaudited 2025 financial information, and the Company\u2019s anticipated SEC filings. These forward-looking statements are based on the current beliefs and expectations of the Company\u2019s management with respect to future events, only speak as of the date that they are made, and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as \u201cfuture,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cpredicts,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201ccontinue,\u201d \u201ccan,\u201d \u201cmay,\u201d \u201clook forward,\u201d \u201caims,\u201d \u201chopes,\u201d and \u201cseeks\u201d and similar terms, although not all forward-looking statements contain such words or expressions. Actual results could differ significantly from those set forth in the forward-looking statements.<\/p> \nImportant factors that may cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, risks relating to the Company\u2019s common stock not trading on a national securities exchange and deregistration from Section 12(b) of the Securities Exchange Act of 1934, as amended; a further material delay in the Company\u2019s financial reporting or ability to hold an annual meeting of stockholders; an inability of the Company to timely prepare its delinquent financial statements; unanticipated factors or factors that the Company currently believes will not cause further delay; the Company\u2019s remediation efforts and preparation of financial statements or other factors that could cause additional delay or adjustments; the possibility that ongoing remediation work or the audit of the Company\u2019s financial statements for the fiscal year ended December 31, 2025 may identify additional errors and material weaknesses or other deficiencies in the Company\u2019s accounting practices; the likelihood that the control deficiencies identified or that may be identified in the future will result in additional material weaknesses in the Company\u2019s internal control over financial reporting; risks relating to the putative securities class action lawsuit filed against the Company, the putative stockholder derivative action filed against the Company, commercial litigation relating to the Company\u2019s representations regarding its financial statements and any other future litigation or investigation relating to the Company\u2019s internal control failures, the completed investigation and reviews or related matters; changes in the financial condition of the markets that the Company serves; risks related to the Company\u2019s recently announced executive leadership transitions; and other factors contained in the \u201cRisk Factors\u201d section and elsewhere in the 2023 and 2024 Form 10-K and the Company\u2019s other filings with the SEC from time to time. The Company does not undertake to update any forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes over time, except as required by law.<\/p> \n\n| \u00a0<\/td>\n<\/tr>\n | \n| \n<\/tr>\n | \n| \u00a0<\/td>\n<\/tr>\n | \n\nTable 1<\/b><\/p><\/td><\/tr>\n\n\nVeradigm Inc.<\/b><\/p><\/td><\/tr>\n\n\nCondensed Consolidated Balance Sheets<\/b><\/p><\/td><\/tr>\n\n\n(In millions)<\/p><\/td><\/tr>\n | \n\n(Unaudited)<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n| \n | \n | \nDecember 31,<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \nDecember 31,<\/b><\/p><\/td><\/tr>\n\n| \n | \n2024<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \n2023<\/b><\/p><\/td><\/tr>\n\n| ASSETS<\/b><\/td>\n | \n | \n | \n | \n<\/tr>\n | \n| Current assets:<\/td>\n | \n | \n | \n | \n<\/tr>\n | \n| Cash and cash equivalents<\/td>\n | \n | \n$294.3<\/p><\/td> | \n | \n$446.6<\/p><\/td><\/tr>\n | \n| Accounts receivable, net of allowance<\/td>\n | \n | \n107.6<\/p><\/td> | \n | \n111.1<\/p><\/td><\/tr>\n | \n| Contract assets, net of allowance<\/td>\n | \n | \n90.9<\/p><\/td> | \n | \n87.3<\/p><\/td><\/tr>\n | \n| Prepaid expenses and other current assets<\/td>\n | \n | \n52.8<\/p><\/td> | \n | \n54.2<\/p><\/td><\/tr>\n | \n| Total current assets<\/td>\n | \n | \n545.6<\/p><\/td> | \n | \n699.2<\/p><\/td><\/tr>\n | \n| Software development costs, net<\/td>\n | \n | \n70.2<\/p><\/td> | \n | \n69.7<\/p><\/td><\/tr>\n | \n| Goodwill<\/td>\n | \n | \n520.7<\/p><\/td> | \n | \n532.5<\/p><\/td><\/tr>\n | \n| Intangible assets, net<\/td>\n | \n | \n80.8<\/p><\/td> | \n | \n75.1<\/p><\/td><\/tr>\n | \n| Investments<\/td>\n | \n | \n98.7<\/p><\/td> | \n | \n98.5<\/p><\/td><\/tr>\n | \n| Deferred taxes, net<\/td>\n | \n | \n1.2<\/p><\/td> | \n | \n66.3<\/p><\/td><\/tr>\n | \n| Other long-term assets<\/td>\n | \n | \n35.1<\/p><\/td> | \n | \n31.6<\/p><\/td><\/tr>\n | \n| Total assets<\/td>\n | \n | \n$1,352.3<\/p><\/td> | \n | \n$1,572.9<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n| LIABILITIES AND STOCKHOLDERS\u2019 EQUITY<\/b><\/td>\n | \n | \n | \n | \n<\/tr>\n | \n| Current liabilities:<\/td>\n | \n | \n | \n | \n<\/tr>\n | \n| Accounts payable<\/td>\n | \n | \n$30.9<\/p><\/td> | \n | \n$21.3<\/p><\/td><\/tr>\n | \n| Accrued expenses<\/td>\n | \n | \n52.0<\/p><\/td> | \n | \n52.0<\/p><\/td><\/tr>\n | \n| Accrued compensation and benefits<\/td>\n | \n | \n30.1<\/p><\/td> | \n | \n27.3<\/p><\/td><\/tr>\n | \n| Deferred revenue<\/td>\n | \n | \n121.1<\/p><\/td> | \n | \n113.0<\/p><\/td><\/tr>\n | \n| Current maturities of long-term debt<\/td>\n | \n | \n154.7<\/p><\/td> | \n | \n205.2<\/p><\/td><\/tr>\n | \n| Customer refunds payable<\/td>\n | \n | \n18.3<\/p><\/td> | \n | \n15.6<\/p><\/td><\/tr>\n | \n| Other current liabilities<\/td>\n | \n | \n14.8<\/p><\/td> | \n | \n11.6<\/p><\/td><\/tr>\n | \n| Total current liabilities<\/td>\n | \n | \n$421.9<\/p><\/td> | \n | \n$446.0<\/p><\/td><\/tr>\n | \n| Long-term debt<\/td>\n | \n | \n72.2<\/p><\/td> | \n | \n0.0<\/p><\/td><\/tr>\n | \n| Other long-term liabilities<\/td>\n | \n | \n54.2<\/p><\/td> | \n | \n52.4<\/p><\/td><\/tr>\n | \n| Total liabilities<\/td>\n | \n | \n548.3<\/p><\/td> | \n | \n498.4<\/p><\/td><\/tr>\n | \n| Total stockholders\u2019 equity<\/td>\n | \n | \n804.0<\/p><\/td> | \n | \n1,074.5<\/p><\/td><\/tr>\n | \n| Total liabilities and stockholders\u2019 equity<\/td>\n | \n | \n$1,352.3<\/p><\/td> | \n | \n$1,572.9<\/p><\/td><\/tr>\n<\/table> \n\n| \n<\/tr>\n | \n| \u00a0<\/td>\n<\/tr>\n | \n| \n<\/tr>\n | \n| \u00a0<\/td>\n<\/tr>\n | \n\nTable 2<\/b><\/p><\/td><\/tr>\n\n\nVeradigm Inc.<\/b><\/p><\/td><\/tr>\n\n\nCondensed Consolidated Statements of Operations<\/b><\/p><\/td><\/tr>\n\n\n(In millions, except per share amounts)<\/p><\/td><\/tr>\n | \n\n(Unaudited)<\/p><\/td><\/tr>\n | \n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \nTwelve Months Ended December 31,<\/b><\/p><\/td><\/tr>\n\n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n2024<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \n2023<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \n2022<\/b><\/p><\/td><\/tr>\n\n| Revenue:<\/td>\n | \n | \n | \n | \n | \n | \n<\/tr>\n | \n| Provider<\/td>\n | \n | \n$473.1<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$492.1<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$465.9<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Payer<\/td>\n | \n | \n67.3<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n72.3<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n56.2<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Life Science<\/td>\n | \n | \n54.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n61.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n65.9<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Total revenue<\/td>\n | \n | \n594.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n626.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n588.0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Cost of revenue:<\/td>\n | \n | \n | \n | \n | \n | \n<\/tr>\n | \n| Provider<\/td>\n | \n | \n231.1<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n222.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n232.8<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Payer<\/td>\n | \n | \n33.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n33.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n27.6<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Life Science<\/td>\n | \n | \n27.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n28.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n19.2<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Total cost of revenue<\/td>\n | \n | \n292.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n284.5<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n279.6<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Gross profit<\/td>\n | \n | \n302.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n341.5<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n308.4<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Gross Margin %<\/td>\n | \n | \n50.8<\/p><\/td> | \n%<\/p><\/td> | \n | \n54.6<\/p><\/td> | \n%<\/p><\/td> | \n | \n52.5<\/p><\/td> | \n%<\/p><\/td><\/tr>\n | \n| Selling, general and administrative expenses<\/td>\n | \n | \n269.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n200.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n169.2<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Research and development<\/td>\n | \n | \n108.3<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n97.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n97.9<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Impairment of goodwill and other assets<\/td>\n | \n | \n108.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n0.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n7.5<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Amortization of intangibles<\/td>\n | \n | \n11.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n8.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n60.9<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Income (loss) from operations<\/td>\n | \n | \n(194.7<\/p><\/td> | \n)<\/p><\/td> | \n | \n34.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n(27.1<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Non-operating income (expense), net<\/td>\n | \n | \n(20.3<\/p><\/td> | \n)<\/p><\/td> | \n | \n25.5<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n(35.6<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Income (loss) from continuing operations before income taxes<\/td>\n | \n | \n(215.0<\/p><\/td> | \n)<\/p><\/td> | \n | \n60.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n(62.7<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Income tax (provision) benefit<\/td>\n | \n | \n(69.4<\/p><\/td> | \n)<\/p><\/td> | \n | \n(10.7<\/p><\/td> | \n)<\/p><\/td> | \n | \n43.8<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Income (loss) from consolidated continuing operations, net of tax<\/td>\n | \n | \n(284.4<\/p><\/td> | \n)<\/p><\/td> | \n | \n49.5<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n(18.9<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Equity in net loss of unconsolidated subsidiaries, net of tax<\/td>\n | \n | \n(7.2<\/p><\/td> | \n)<\/p><\/td> | \n | \n(0.3<\/p><\/td> | \n)<\/p><\/td> | \n | \n(1.1<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Income (loss) from continuing operations, net of tax<\/td>\n | \n | \n(291.6<\/p><\/td> | \n)<\/p><\/td> | \n | \n49.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n(20.0<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Income (loss) from discontinued operations, net of tax<\/td>\n | \n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n(66.4<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Net income (loss) attributable to Veradigm Inc.<\/td>\n | \n | \n($291.6<\/p><\/td> | \n)<\/p><\/td> | \n | \n$49.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n($86.4<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n| Diluted earnings per Common Share:<\/td>\n | \n | \n | \n | \n | \n | \n<\/tr>\n | \n| Income (loss) from continuing operations, net of tax<\/td>\n | \n | \n($291.6<\/p><\/td> | \n)<\/p><\/td> | \n | \n$49.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n($20.0<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \nPlus: Interest expense, net of tax1<\/sup><\/td>\n| \n | \n$0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$2.5<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$0.0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \nIncome (loss) from continuing operations2<\/sup><\/td>\n| \n | \n(291.6<\/p><\/td> | \n)<\/p><\/td> | \n | \n51.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n(20.0<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Income (loss) from discontinued operations, net of tax<\/td>\n | \n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n(66.4<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \nNet income (loss)attributable to Veradigm Inc. 2<\/sup><\/td>\n| \n | \n($291.6<\/p><\/td> | \n)<\/p><\/td> | \n | \n$51.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n($86.4<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n| Income (loss) from continuing operations per share - basic<\/td>\n | \n | \n($2.70<\/p><\/td> | \n)<\/p><\/td> | \n | \n$0.46<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n($0.18<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Income (loss) from discontinued operations per share - basic<\/td>\n | \n | \n$0.00<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$0.00<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n($0.59<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Income (loss) per share - basic<\/td>\n | \n | \n($2.70<\/p><\/td> | \n)<\/p><\/td> | \n | \n$0.46<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n($0.77<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \nIncome (loss) from continuing operations per share - diluted2<\/sup><\/td>\n| \n | \n($2.70<\/p><\/td> | \n)<\/p><\/td> | \n | \n$0.41<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n($0.18<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Income (loss) from discontinued operations per share - diluted<\/td>\n | \n | \n$0.00<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$0.00<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n($0.59<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \nIncome (loss) per share - diluted2<\/sup><\/td>\n| \n | \n($2.70<\/p><\/td> | \n)<\/p><\/td> | \n | \n$0.41<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n($0.77<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n| Weighted average common shares outstanding:<\/td>\n | \n | \n | \n | \n | \n | \n<\/tr>\n | \n| Basic<\/td>\n | \n | \n108.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n107.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n112.1<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Diluted<\/td>\n | \n | \n108.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n124.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n112.1<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n1 <\/sup>Associated with 0.875% Convertible Senior Notes<\/td>\n<\/tr>\n\n2 <\/sup>Net of tax after the effect of assumed conversions of convertible notes<\/td>\n<\/tr>\n<\/table>\n\n| \n<\/tr>\n | \n| \u00a0<\/td>\n<\/tr>\n | \n| \n<\/tr>\n | \n| \u00a0<\/td>\n<\/tr>\n | \n\nTable 3<\/b><\/p><\/td><\/tr>\n\n\nVeradigm Inc.<\/b><\/p><\/td><\/tr>\n\n\nCondensed Non-GAAP Financial Information<\/b><\/p><\/td><\/tr>\n\n\n(In millions, except per share amounts and percentages)<\/p><\/td><\/tr>\n | \n\n(Unaudited)<\/p><\/td><\/tr>\n | \n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\n\u00a0<\/p><\/td> | \nTwelve Months Ended December 31,<\/b><\/p><\/td><\/tr>\n\n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\n\u00a0<\/p><\/td> | \n2024<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \n2023<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \n2022<\/b><\/p><\/td><\/tr>\n\n| Revenue, GAAP<\/td>\n | \n$594.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$626.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$588.0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Transaction other<\/td>\n | \n(0.5<\/p><\/td> | \n)<\/p><\/td> | \n | \n(19.4<\/p><\/td> | \n)<\/p><\/td> | \n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Non-GAAP Revenue<\/b><\/td>\n | \n$593.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$606.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$588.0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n| Gross profit, GAAP<\/td>\n | \n$302.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$341.5<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$308.4<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| GAAP Gross margin<\/i><\/td>\n | \n50.8<\/i><\/p><\/td> | \n%<\/i><\/p><\/td> | \n | \n54.6<\/i><\/p><\/td> | \n%<\/i><\/p><\/td> | \n | \n52.5<\/i><\/p><\/td> | \n%<\/i><\/p><\/td><\/tr>\n\n| Depreciation and amortization<\/td>\n | \n32.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n38.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n43.8<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Stock-based compensation expense<\/td>\n | \n1.5<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n0.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n1.3<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Transaction and other<\/td>\n | \n0.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n(19.4<\/p><\/td> | \n)<\/p><\/td> | \n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Total non-GAAP gross profit<\/td>\n | \n$336.8<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$361.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$353.5<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Non-GAAP Gross margin<\/i><\/td>\n | \n56.7<\/i><\/p><\/td> | \n%<\/i><\/p><\/td> | \n | \n59.6<\/i><\/p><\/td> | \n%<\/i><\/p><\/td> | \n | \n60.1<\/i><\/p><\/td> | \n%<\/i><\/p><\/td><\/tr>\n\n| \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n| Net income (loss) attributable to Veradigm Inc.<\/td>\n | \n($291.6<\/p><\/td> | \n)<\/p><\/td> | \n | \n$49.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n($86.4<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Net Income margin<\/i><\/td>\n | \n-49.1<\/i><\/p><\/td> | \n%<\/i><\/p><\/td> | \n | \n7.9<\/i><\/p><\/td> | \n%<\/i><\/p><\/td> | \n | \n-14.7<\/i><\/p><\/td> | \n%<\/i><\/p><\/td><\/tr>\n\n| Less:<\/td>\n | \n | \n | \n | \n | \n<\/tr>\n | \n| Loss (income) from discontinued operations<\/td>\n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n7.1<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Loss (gain) on sale of business, net from discontinued operations<\/td>\n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n10.3<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Income tax provision (benefit) from discontinued operations<\/td>\n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n49.0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Income (loss) from continuing operations, net of tax, GAAP<\/td>\n | \n($291.6<\/p><\/td> | \n)<\/p><\/td> | \n | \n$49.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n($20.0<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Plus:<\/td>\n | \n | \n | \n | \n | \n<\/tr>\n | \n| Non-operating income (expense), net<\/td>\n | \n20.3<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n(25.5<\/p><\/td> | \n)<\/p><\/td> | \n | \n35.6<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Equity in net loss of unconsolidated subsidiaries, net of tax<\/td>\n | \n7.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n0.3<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n1.1<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Depreciation and amortization<\/td>\n | \n45.8<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n52.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n113.5<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Income tax (benefit) provision<\/td>\n | \n69.5<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n10.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n(43.8<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Stock-based compensation expense<\/td>\n | \n24.5<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n16.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n29.6<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Impairment of goodwill and other assets<\/td>\n | \n108.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n0.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n7.5<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Transaction and other<\/td>\n | \n110.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n27.8<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n17.9<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Adjusted EBITDA<\/td>\n | \n$94.1<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$131.5<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$141.4<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n| Adjusted EBITDA margin<\/i><\/td>\n | \n15.8<\/i><\/p><\/td> | \n%<\/i><\/p><\/td> | \n | \n21.7<\/i><\/p><\/td> | \n%<\/i><\/p><\/td> | \n | \n24.0<\/i><\/p><\/td> | \n%<\/i><\/p><\/td><\/tr>\n\n| \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n| Net income (loss) attributable to Veradigm Inc.<\/td>\n | \n($291.6<\/p><\/td> | \n)<\/p><\/td> | \n | \n$49.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n($86.4<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Loss (income) from discontinued operations<\/td>\n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n7.1<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| (Gain) on sale of business, net from discontinued operations<\/td>\n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n10.3<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Income tax provision (benefit) from discontinued operations<\/td>\n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n49.0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Income (loss) from continuing operations<\/td>\n | \n($291.6<\/p><\/td> | \n)<\/p><\/td> | \n | \n$49.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n($20.0<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Acquisition-related amortization<\/td>\n | \n15.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n14.3<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n67.7<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Stock-based compensation expense<\/td>\n | \n24.5<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n16.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n29.6<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Transaction and other<\/td>\n | \n110.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n27.8<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n17.9<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Other non-operating (income) expense<\/td>\n | \n28.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n2.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n16.0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Impairment of goodwill and other assets<\/td>\n | \n108.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n0.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n7.5<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Tax rate alignment<\/td>\n | \n52.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n(18.4<\/p><\/td> | \n)<\/p><\/td> | \n | \n(62.1<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Non-GAAP net income<\/td>\n | \n47.8<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n91.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n56.6<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \nAdd: Interest expense, net of tax, associated with asssumed conversion of convertible notes1<\/sup><\/td>\n\n2.3<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n2.5<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n2.0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Non-GAAP net income, after effect of assumed conversions<\/td>\n | \n$50.1<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$94.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$58.6<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n| GAAP effective tax rate<\/td>\n | \n-32<\/p><\/td> | \n%<\/p><\/td> | \n | \n18<\/p><\/td> | \n%<\/p><\/td> | \n | \n70<\/p><\/td> | \n%<\/p><\/td><\/tr>\n | \n| Non-GAAP effective tax rate<\/td>\n | \n24<\/p><\/td> | \n%<\/p><\/td> | \n | \n24<\/p><\/td> | \n%<\/p><\/td> | \n | \n24<\/p><\/td> | \n%<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n| Weighted shares outstanding - basic<\/td>\n | \n108.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n107.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n112.1<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Weighted shares outstanding - diluted<\/td>\n | \n108.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n124.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n112.1<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| The dilutive impact inclusive of convertible notes and restricted stock<\/td>\n | \n16.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n0.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n20.3<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| Non-GAAP Weighted shares outstanding - diluted<\/td>\n | \n124.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n124.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n132.4<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \nIncome (loss) from continuing operations per share - diluted2<\/sup><\/td>\n\n($2.70<\/p><\/td> | \n)<\/p><\/td> | \n | \n$0.41<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n($0.18<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n| Income (loss) from discontinued operations per share - diluted<\/td>\n | \n$0.00<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$0.00<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n($0.59<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \nIncome (loss) per share - diluted2<\/sup><\/td>\n\n($2.70<\/p><\/td> | \n)<\/p><\/td> | \n | \n$0.41<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n($0.77<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \nNon-GAAP Net Income (loss) per share - diluted2<\/sup><\/td>\n\n$0.40<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$0.76<\/p><\/td> | \n\u00a0<\/p><\/td> | \n | \n$0.44<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n1<\/sup> Associated with 0.875% Convertible Senior Notes<\/td>\n<\/tr>\n\n2 <\/sup>Net of tax after the effect of assumed conversions of convertible notes and restricted stock<\/td>\n<\/tr>\n<\/table>\n\n| \n<\/tr>\n | \n| \u00a0<\/td>\n<\/tr>\n | \n| \n<\/tr>\n | \n| \u00a0<\/td>\n<\/tr>\n | \n\nTable 4<\/b><\/p><\/td><\/tr>\n\n\nVeradigm Inc.<\/b><\/p><\/td><\/tr>\n\n\nSupplemental Condensed Non-GAAP Financial Information<\/b><\/p><\/td><\/tr>\n\n\n(In millions)<\/p><\/td><\/tr>\n | \n\n(unaudited)<\/p><\/td><\/tr>\n | \n| \n | \u00a0<\/td>\n<\/tr>\n | \n| \n | \n2023<\/b><\/p><\/td> | \n | \n2024<\/b><\/p><\/td><\/tr>\n\n| \n | Q1<\/b><\/td>\n | Q2<\/b><\/td>\n | Q3<\/b><\/td>\n | Q4<\/b><\/td>\n | Total<\/b><\/td>\n | \n | Q1<\/b><\/td>\n | Q2<\/b><\/td>\n | Q3<\/b><\/td>\n | Q4<\/b><\/td>\n | Total<\/b><\/td>\n<\/tr>\n\n| Provider<\/span><\/b><\/td>\n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n<\/tr>\n | \n| Revenue, Non-GAAP<\/td>\n | \n$117.5<\/p><\/td> | \n$118.1<\/p><\/td> | \n$117.4<\/p><\/td> | \n$119.7<\/p><\/td> | \n$472.7<\/p><\/td> | \n | \n$115.9<\/p><\/td> | \n$122.3<\/p><\/td> | \n$117.2<\/p><\/td> | \n$117.2<\/p><\/td> | \n$472.6<\/p><\/td><\/tr>\n | \n| Gross profit, Non-GAAP<\/td>\n | \n$70.2<\/p><\/td> | \n$68.9<\/p><\/td> | \n$70.1<\/p><\/td> | \n$70.5<\/p><\/td> | \n$279.7<\/p><\/td> | \n | \n$66.6<\/p><\/td> | \n$70.6<\/p><\/td> | \n$65.2<\/p><\/td> | \n$63.7<\/p><\/td> | \n$266.1<\/p><\/td><\/tr>\n | \n| Gross margin, Non-GAAP<\/td>\n | \n59.7%<\/p><\/td> | \n58.3%<\/p><\/td> | \n59.7%<\/p><\/td> | \n58.9%<\/p><\/td> | \n59.2%<\/p><\/td> | \n | \n57.5%<\/p><\/td> | \n57.7%<\/p><\/td> | \n55.6%<\/p><\/td> | \n54.4%<\/p><\/td> | \n56.3%<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n| Payer<\/span><\/b><\/td>\n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n<\/tr>\n | \n| Revenue<\/td>\n | \n$18.7<\/p><\/td> | \n$18.9<\/p><\/td> | \n$17.0<\/p><\/td> | \n$17.7<\/p><\/td> | \n$72.3<\/p><\/td> | \n | \n$18.4<\/p><\/td> | \n$16.9<\/p><\/td> | \n$15.2<\/p><\/td> | \n$16.8<\/p><\/td> | \n$67.3<\/p><\/td><\/tr>\n | \n| Gross profit, Non-GAAP<\/td>\n | \n$12.5<\/p><\/td> | \n$10.8<\/p><\/td> | \n$9.9<\/p><\/td> | \n$11.0<\/p><\/td> | \n$44.2<\/p><\/td> | \n | \n$11.5<\/p><\/td> | \n$10.1<\/p><\/td> | \n$8.4<\/p><\/td> | \n$9.5<\/p><\/td> | \n$39.5<\/p><\/td><\/tr>\n | \n| Gross margin, Non-GAAP<\/td>\n | \n66.8%<\/p><\/td> | \n57.1%<\/p><\/td> | \n58.2%<\/p><\/td> | \n62.1%<\/p><\/td> | \n61.1%<\/p><\/td> | \n | \n62.5%<\/p><\/td> | \n59.8%<\/p><\/td> | \n55.3%<\/p><\/td> | \n56.5%<\/p><\/td> | \n58.7%<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n| Life Science<\/span><\/b><\/td>\n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n<\/tr>\n | \n| Revenue<\/td>\n | \n$13.1<\/p><\/td> | \n$17.6<\/p><\/td> | \n$14.1<\/p><\/td> | \n$16.8<\/p><\/td> | \n$61.6<\/p><\/td> | \n | \n$11.8<\/p><\/td> | \n$13.5<\/p><\/td> | \n$12.7<\/p><\/td> | \n$16.0<\/p><\/td> | \n$54.0<\/p><\/td><\/tr>\n | \n| Gross profit, Non-GAAP<\/td>\n | \n$7.7<\/p><\/td> | \n$11.1<\/p><\/td> | \n$8.0<\/p><\/td> | \n$10.9<\/p><\/td> | \n$37.7<\/p><\/td> | \n | \n$5.5<\/p><\/td> | \n$8.0<\/p><\/td> | \n$7.4<\/p><\/td> | \n$10.3<\/p><\/td> | \n$31.2<\/p><\/td><\/tr>\n | \n| Gross margin, Non-GAAP<\/td>\n | \n58.8%<\/p><\/td> | \n63.1%<\/p><\/td> | \n56.7%<\/p><\/td> | \n64.9%<\/p><\/td> | \n61.2%<\/p><\/td> | \n | \n46.6%<\/p><\/td> | \n59.3%<\/p><\/td> | \n58.3%<\/p><\/td> | \n64.4%<\/p><\/td> | \n57.8%<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n| Total Veradigm<\/span><\/b><\/td>\n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n<\/tr>\n | \n| Revenue, Non-GAAP<\/td>\n | \n$149.3<\/p><\/td> | \n$154.6<\/p><\/td> | \n$148.5<\/p><\/td> | \n$154.2<\/p><\/td> | \n$606.6<\/p><\/td> | \n | \n$146.1<\/p><\/td> | \n$152.7<\/p><\/td> | \n$145.1<\/p><\/td> | \n$150.0<\/p><\/td> | \n$593.9<\/p><\/td><\/tr>\n | \n| Gross profit, Non-GAAP<\/td>\n | \n$90.4<\/p><\/td> | \n$90.8<\/p><\/td> | \n$88.0<\/p><\/td> | \n$92.4<\/p><\/td> | \n$361.6<\/p><\/td> | \n | \n$83.6<\/p><\/td> | \n$88.7<\/p><\/td> | \n$81.0<\/p><\/td> | \n$83.5<\/p><\/td> | \n$336.8<\/p><\/td><\/tr>\n | \n| Gross margin, Non-GAAP<\/td>\n | \n60.5%<\/p><\/td> | \n58.7%<\/p><\/td> | \n59.3%<\/p><\/td> | \n59.9%<\/p><\/td> | \n59.6%<\/p><\/td> | \n | \n57.2%<\/p><\/td> | \n58.1%<\/p><\/td> | \n55.8%<\/p><\/td> | \n55.7%<\/p><\/td> | \n56.7%<\/p><\/td><\/tr>\n | \n| Adjusted EBITDA<\/td>\n | \n$31.1<\/p><\/td> | \n$38.2<\/p><\/td> | \n$34.8<\/p><\/td> | \n$27.4<\/p><\/td> | \n$131.5<\/p><\/td> | \n | \n$22.4<\/p><\/td> | \n$27.6<\/p><\/td> | \n$19.1<\/p><\/td> | \n$25.0<\/p><\/td> | \n$94.1<\/p><\/td><\/tr>\n | \n| Adjusted EBITDA margin<\/td>\n | \n20.8%<\/p><\/td> | \n24.7%<\/p><\/td> | \n23.4%<\/p><\/td> | \n17.8%<\/p><\/td> | \n21.7%<\/p><\/td> | \n | \n15.3%<\/p><\/td> | \n18.1%<\/p><\/td> | \n13.2%<\/p><\/td> | \n16.7%<\/p><\/td> | \n15.8%<\/p><\/td><\/tr>\n | \n| Non-GAAP net income, after effect of assumed conversions<\/td>\n | \n$22.8<\/p><\/td> | \n$20.0<\/p><\/td> | \n$34.3<\/p><\/td> | \n$17.1<\/p><\/td> | \n$94.2<\/p><\/td> | \n | \n$12.9<\/p><\/td> | \n$13.1<\/p><\/td> | \n$19.5<\/p><\/td> | \n$4.6<\/p><\/td> | \n$50.1<\/p><\/td><\/tr>\n | \n| Non-GAAP Weighted shares outstanding - diluted<\/td>\n | \n124.4<\/p><\/td> | \n123.6<\/p><\/td> | \n124.5<\/p><\/td> | \n124.5<\/p><\/td> | \n124.6<\/p><\/td> | \n | \n124.4<\/p><\/td> | \n124.4<\/p><\/td> | \n125.4<\/p><\/td> | \n126.0<\/p><\/td> | \n124.9<\/p><\/td><\/tr>\n | \nNon-GAAP Income (loss) per share - diluted1<\/sup><\/td>\n\n$0.18<\/p><\/td> | \n$0.16<\/p><\/td> | \n$0.28<\/p><\/td> | \n$0.14<\/p><\/td> | \n$0.76<\/p><\/td> | \n | \n$0.10<\/p><\/td> | \n$0.11<\/p><\/td> | \n$0.16<\/p><\/td> | \n$0.04<\/p><\/td> | \n$0.40<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n1<\/sup> Net of tax after the effect of assumed conversions of convertible notes and restricted stock<\/td>\n<\/tr>\n<\/table>\n\n| \n<\/tr>\n | \n| \u00a0<\/td>\n<\/tr>\n | \n| \n<\/tr>\n | \n| \u00a0<\/td>\n<\/tr>\n | \n\nTable 5<\/b><\/p><\/td><\/tr>\n\n\nVeradigm Inc.<\/b><\/p><\/td><\/tr>\n\n\nSupplemental Non-GAAP Financial Information Reconciliation - Financial Trend Details<\/b><\/p><\/td><\/tr>\n\n\n(In millions)<\/p><\/td><\/tr>\n | \n\n(unaudited)<\/p><\/td><\/tr>\n | \n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n2023<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \n2024<\/b><\/p><\/td><\/tr>\n\n| \n | \n | Q1<\/b><\/td>\n | Q2<\/b><\/td>\n | Q3<\/b><\/td>\n | Q4<\/b><\/td>\n | Total<\/b><\/td>\n | \n | Q1<\/b><\/td>\n | Q2<\/b><\/td>\n | Q3<\/b><\/td>\n | Q4<\/b><\/td>\n | Total<\/b><\/td>\n<\/tr>\n\n| Provider<\/span><\/b><\/td>\n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n<\/tr>\n | \n| Revenue, GAAP<\/b><\/td>\n | \n | \n$117.7<\/b><\/p><\/td> | \n$136.7<\/b><\/p><\/td> | \n$117.7<\/b><\/p><\/td> | \n$120.0<\/b><\/p><\/td> | \n$492.1<\/b><\/p><\/td> | \n | \n$116.2<\/b><\/p><\/td> | \n$122.4<\/b><\/p><\/td> | \n$117.3<\/b><\/p><\/td> | \n$117.2<\/b><\/p><\/td> | \n$473.1<\/b><\/p><\/td><\/tr>\n\n| Transaction and other<\/td>\n | \n | \n(0.2)<\/p><\/td> | \n(18.6)<\/p><\/td> | \n(0.3)<\/p><\/td> | \n(0.3)<\/p><\/td> | \n(19.4)<\/p><\/td> | \n | \n(0.3)<\/p><\/td> | \n(0.1)<\/p><\/td> | \n(0.1)<\/p><\/td> | \n0.0<\/p><\/td> | \n(0.5)<\/p><\/td><\/tr>\n | \n| Revenue, Non-GAAP<\/b><\/td>\n | \n | \n$117.5<\/b><\/p><\/td> | \n$118.1<\/b><\/p><\/td> | \n$117.4<\/b><\/p><\/td> | \n$119.7<\/b><\/p><\/td> | \n$472.7<\/b><\/p><\/td> | \n | \n$115.9<\/b><\/p><\/td> | \n$122.3<\/b><\/p><\/td> | \n$117.2<\/b><\/p><\/td> | \n$117.2<\/b><\/p><\/td> | \n$472.6<\/b><\/p><\/td><\/tr>\n\n| \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n| Gross profit, GAAP<\/b><\/td>\n | \n | \n$62.2<\/b><\/p><\/td> | \n$80.0<\/b><\/p><\/td> | \n$63.1<\/b><\/p><\/td> | \n$64.2<\/b><\/p><\/td> | \n$269.5<\/b><\/p><\/td> | \n | \n$60.1<\/b><\/p><\/td> | \n$64.9<\/b><\/p><\/td> | \n$59.1<\/b><\/p><\/td> | \n$57.9<\/b><\/p><\/td> | \n$242.0<\/b><\/p><\/td><\/tr>\n\n| Gross margin, GAAP<\/i><\/td>\n | \n | \n52.8%<\/i><\/p><\/td> | \n58.5%<\/i><\/p><\/td> | \n53.6%<\/i><\/p><\/td> | \n53.5%<\/i><\/p><\/td> | \n54.8%<\/i><\/p><\/td> | \n | \n51.7%<\/i><\/p><\/td> | \n53.0%<\/i><\/p><\/td> | \n50.4%<\/i><\/p><\/td> | \n49.4%<\/i><\/p><\/td> | \n51.2%<\/i><\/p><\/td><\/tr>\n\n| Depreciation and amortization<\/td>\n | \n | \n7.9<\/p><\/td> | \n7.4<\/p><\/td> | \n7.1<\/p><\/td> | \n6.5<\/p><\/td> | \n28.9<\/p><\/td> | \n | \n6.1<\/p><\/td> | \n5.7<\/p><\/td> | \n5.9<\/p><\/td> | \n5.1<\/p><\/td> | \n22.8<\/p><\/td><\/tr>\n | \n| Stock-based compensation expense<\/td>\n | \n | \n0.3<\/p><\/td> | \n0.1<\/p><\/td> | \n0.2<\/p><\/td> | \n0.1<\/p><\/td> | \n0.7<\/p><\/td> | \n | \n0.3<\/p><\/td> | \n0.1<\/p><\/td> | \n0.2<\/p><\/td> | \n0.7<\/p><\/td> | \n1.3<\/p><\/td><\/tr>\n | \n| Transaction and other<\/td>\n | \n | \n(0.2)<\/p><\/td> | \n(18.6)<\/p><\/td> | \n(0.3)<\/p><\/td> | \n(0.3)<\/p><\/td> | \n(19.4)<\/p><\/td> | \n | \n0.1<\/p><\/td> | \n(0.1)<\/p><\/td> | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n(0.0)<\/p><\/td><\/tr>\n | \n| Gross profit, Non-GAAP<\/b><\/td>\n | \n | \n$70.2<\/b><\/p><\/td> | \n$68.9<\/b><\/p><\/td> | \n$70.1<\/b><\/p><\/td> | \n$70.5<\/b><\/p><\/td> | \n$279.7<\/b><\/p><\/td> | \n | \n$66.6<\/b><\/p><\/td> | \n$70.6<\/b><\/p><\/td> | \n$65.2<\/b><\/p><\/td> | \n$63.7<\/b><\/p><\/td> | \n$266.1<\/b><\/p><\/td><\/tr>\n\n| Gross margin, Non-GAAP<\/i><\/td>\n | \n | \n59.7%<\/i><\/p><\/td> | \n58.3%<\/i><\/p><\/td> | \n59.7%<\/i><\/p><\/td> | \n58.9%<\/i><\/p><\/td> | \n59.2%<\/i><\/p><\/td> | \n | \n57.5%<\/i><\/p><\/td> | \n57.7%<\/i><\/p><\/td> | \n55.6%<\/i><\/p><\/td> | \n54.4%<\/i><\/p><\/td> | \n56.3%<\/i><\/p><\/td><\/tr>\n\n| Payer<\/span><\/b><\/td>\n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n<\/tr>\n | \n| Revenue, GAAP<\/b><\/td>\n | \n | \n$18.7<\/b><\/p><\/td> | \n$18.9<\/b><\/p><\/td> | \n$17.0<\/b><\/p><\/td> | \n$17.7<\/b><\/p><\/td> | \n$72.3<\/b><\/p><\/td> | \n | \n$18.4<\/b><\/p><\/td> | \n$16.9<\/b><\/p><\/td> | \n$15.2<\/b><\/p><\/td> | \n$16.8<\/b><\/p><\/td> | \n$67.3<\/b><\/p><\/td><\/tr>\n\n| \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n| Gross profit, GAAP<\/b><\/td>\n | \n | \n$10.9<\/b><\/p><\/td> | \n$9.3<\/b><\/p><\/td> | \n$8.6<\/b><\/p><\/td> | \n$9.8<\/b><\/p><\/td> | \n$38.6<\/b><\/p><\/td> | \n | \n$9.8<\/b><\/p><\/td> | \n$8.5<\/b><\/p><\/td> | \n$7.0<\/b><\/p><\/td> | \n$8.1<\/b><\/p><\/td> | \n$33.4<\/b><\/p><\/td><\/tr>\n\n| Gross margin, GAAP<\/i><\/td>\n | \n | \n58.3%<\/i><\/p><\/td> | \n49.2%<\/i><\/p><\/td> | \n50.6%<\/i><\/p><\/td> | \n55.4%<\/i><\/p><\/td> | \n53.4%<\/i><\/p><\/td> | \n | \n53.3%<\/i><\/p><\/td> | \n50.3%<\/i><\/p><\/td> | \n46.1%<\/i><\/p><\/td> | \n48.2%<\/i><\/p><\/td> | \n49.6%<\/i><\/p><\/td><\/tr>\n\n| Depreciation and amortization<\/td>\n | \n | \n1.5<\/p><\/td> | \n1.5<\/p><\/td> | \n1.3<\/p><\/td> | \n1.2<\/p><\/td> | \n5.5<\/p><\/td> | \n | \n1.5<\/p><\/td> | \n1.6<\/p><\/td> | \n1.4<\/p><\/td> | \n1.4<\/p><\/td> | \n5.9<\/p><\/td><\/tr>\n | \n| Stock-based compensation expense<\/td>\n | \n | \n0.1<\/p><\/td> | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n0.1<\/p><\/td> | \n | \n0.1<\/p><\/td> | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n0.1<\/p><\/td><\/tr>\n | \n| Transaction and other<\/td>\n | \n | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n | \n0.1<\/p><\/td> | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n0.1<\/p><\/td><\/tr>\n | \n| Gross profit, Non-GAAP<\/b><\/td>\n | \n | \n$12.5<\/b><\/p><\/td> | \n$10.8<\/b><\/p><\/td> | \n$9.9<\/b><\/p><\/td> | \n$11.0<\/b><\/p><\/td> | \n$44.2<\/b><\/p><\/td> | \n | \n$11.5<\/b><\/p><\/td> | \n$10.1<\/b><\/p><\/td> | \n$8.4<\/b><\/p><\/td> | \n$9.5<\/b><\/p><\/td> | \n$39.5<\/b><\/p><\/td><\/tr>\n\n| Gross margin, Non-GAAP<\/i><\/td>\n | \n | \n66.8%<\/i><\/p><\/td> | \n57.1%<\/i><\/p><\/td> | \n58.2%<\/i><\/p><\/td> | \n62.1%<\/i><\/p><\/td> | \n61.1%<\/i><\/p><\/td> | \n | \n62.5%<\/i><\/p><\/td> | \n59.8%<\/i><\/p><\/td> | \n55.3%<\/i><\/p><\/td> | \n56.5%<\/i><\/p><\/td> | \n58.7%<\/i><\/p><\/td><\/tr>\n\n| Life Science<\/span><\/b><\/td>\n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n<\/tr>\n | \n| Revenue, GAAP<\/b><\/td>\n | \n | \n$13.1<\/b><\/p><\/td> | \n$17.6<\/b><\/p><\/td> | \n$14.1<\/b><\/p><\/td> | \n$16.8<\/b><\/p><\/td> | \n$61.6<\/b><\/p><\/td> | \n | \n$11.8<\/b><\/p><\/td> | \n$13.5<\/b><\/p><\/td> | \n$12.7<\/b><\/p><\/td> | \n$16.0<\/b><\/p><\/td> | \n$54.0<\/b><\/p><\/td><\/tr>\n\n| \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n| Gross profit, GAAP<\/b><\/td>\n | \n | \n$6.6<\/b><\/p><\/td> | \n$10.1<\/b><\/p><\/td> | \n$7.0<\/b><\/p><\/td> | \n$9.7<\/b><\/p><\/td> | \n$33.4<\/b><\/p><\/td> | \n | \n$4.5<\/b><\/p><\/td> | \n$7.1<\/b><\/p><\/td> | \n$6.3<\/b><\/p><\/td> | \n$8.9<\/b><\/p><\/td> | \n$26.8<\/b><\/p><\/td><\/tr>\n\n| Gross margin, GAAP<\/i><\/td>\n | \n | \n50.4%<\/i><\/p><\/td> | \n57.4%<\/i><\/p><\/td> | \n49.6%<\/i><\/p><\/td> | \n57.7%<\/i><\/p><\/td> | \n54.2%<\/i><\/p><\/td> | \n | \n38.1%<\/i><\/p><\/td> | \n52.6%<\/i><\/p><\/td> | \n49.6%<\/i><\/p><\/td> | \n55.6%<\/i><\/p><\/td> | \n49.6%<\/i><\/p><\/td><\/tr>\n\n| Depreciation and amortization<\/td>\n | \n | \n1.1<\/p><\/td> | \n1.0<\/p><\/td> | \n1.0<\/p><\/td> | \n1.1<\/p><\/td> | \n4.2<\/p><\/td> | \n | \n0.9<\/p><\/td> | \n0.9<\/p><\/td> | \n1.0<\/p><\/td> | \n1.4<\/p><\/td> | \n4.2<\/p><\/td><\/tr>\n | \n| Stock-based compensation expense<\/td>\n | \n | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n0.1<\/p><\/td> | \n0.1<\/p><\/td> | \n | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n0.1<\/p><\/td> | \n0.0<\/p><\/td> | \n0.1<\/p><\/td><\/tr>\n | \n| Transaction and other<\/td>\n | \n | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n | \n0.1<\/p><\/td> | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n0.0<\/p><\/td> | \n0.1<\/p><\/td><\/tr>\n | \n| Gross profit, Non-GAAP<\/b><\/td>\n | \n | \n$7.7<\/b><\/p><\/td> | \n$11.1<\/b><\/p><\/td> | \n$8.0<\/b><\/p><\/td> | \n$10.9<\/b><\/p><\/td> | \n$37.7<\/b><\/p><\/td> | \n | \n$5.5<\/b><\/p><\/td> | \n$8.0<\/b><\/p><\/td> | \n$7.4<\/b><\/p><\/td> | \n$10.3<\/b><\/p><\/td> | \n$31.2<\/b><\/p><\/td><\/tr>\n\n| Gross margin, Non-GAAP<\/i><\/td>\n | \n | \n58.8%<\/i><\/p><\/td> | \n63.1%<\/i><\/p><\/td> | \n56.7%<\/i><\/p><\/td> | \n64.9%<\/i><\/p><\/td> | \n61.2%<\/i><\/p><\/td> | \n | \n46.6%<\/i><\/p><\/td> | \n59.3%<\/i><\/p><\/td> | \n58.3%<\/i><\/p><\/td> | \n64.4%<\/i><\/p><\/td> | \n57.8%<\/i><\/p><\/td><\/tr>\n<\/table>\n\n| \n<\/tr>\n | \n| \u00a0<\/td>\n<\/tr>\n | \n| \n<\/tr>\n | \n| \u00a0<\/td>\n<\/tr>\n | \n | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
![](\"https:\/\/mms.businesswire.com\/media\/20260526287828\/en\/1867052\/22\/VeradigmR-logo.jpg\"){kind=logo}
<\/a>![](\"https:\/\/mms.businesswire.com\/media\/20260526287828\/en\/1867052\/21\/VeradigmR-logo.jpg\"){kind=logo}
<\/a>